Please login to Zacks.com or register to post a comment.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Rockville, Maryland-based Synutra International, Inc ( SYUT - Snapshot Report ) recently announced that its Chief Financial Officer (CFO) Donghao Yang has resigned to pursue other opportunities.
Yang joined the infant formula company in China as CFO in June 2010 and utilized all his expertise and experience to improve the company’s top line and narrow down the losses. Yang has an experience of over 16 years in corporate finance, commodity trading and international business development. He will however, continue to guide the company as a member of the board.
Until a permanent CFO is selected, Weiguo Zhang will stand in as the CFO. He has been President and Chief Operating Officer since 2005. Zhang joined Synutra in 2001 and is currently responsible for financial and marketing operations of the company, including investor relations, corporate development, and international strategic development. Mr. Zhang is also a director and a member of the compensation committee and audit committee of RINO International Corporation ( RINO ) .
Prior to joining Synutra, Zhang was the managing director of Bambridge International, Ltd., which he founded in 1995.
The company’s search for a new CFO has begun, but we believe Synutra is in safe hands in the interim.
In the recently concluded first quarter 2012, the company reported a loss of 17 cents, which was worse than the Zacks Consensus Estimate of a loss of 7 cents per share and the year-ago quarter's earnings of 19 cents a share.
The company’s lower-than-expected results were due to sluggish revenue. During the quarter,net sales dipped 47.8% year over year to $43.8 million.
The Zacks Consensus Estimates for 2012 and 2013 are pegged at 25 cents and 70 cents per share, respectively. The company currently retains a Zacks #3 Rank, which translates into a short-term Hold rating on the stock. We also reiterate our long-term Neutral recommendation on the stock.
Read the full Snapshot Report on SYUT
Read the full on RINO